Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effects of NGI226 Microparticles for Patients with Achilles Tendinopathy

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Achilles tendinopathy, a condition that causes pain and swelling in the tendon at the back of the ankle. The study will evaluate a new treatment called NGI226, which is a powder mixed into a liquid and injected near the affected tendon. The purpose of the study is to assess the safety and initial effectiveness of this treatment in helping the tendon heal.

Participants in the study will receive either the NGI226 treatment or a placebo, which looks like the treatment but does not contain the active substance. The study is designed to be "blinded," meaning neither the participants nor the researchers will know who receives the actual treatment or the placebo. This helps ensure the results are unbiased. The study will monitor participants for any side effects and changes in their symptoms over time.

The trial will involve regular check-ups to assess the condition of the tendon and overall health. This includes looking at changes in pain, swelling, and other symptoms, as well as conducting tests like blood work and heart monitoring. The study aims to provide valuable information on whether NGI226 can be a safe and effective option for people suffering from Achilles tendinopathy.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit and consent

    Upon joining the study, you will have an initial visit where you will be asked to provide written informed consent. This means you agree to participate in the study after understanding all the details and potential risks.

    During this visit, your eligibility will be confirmed based on specific criteria, such as age and the presence of Achilles tendinopathy diagnosed through clinical examination and imaging tests like ultrasound or MRI.

  2. Step 2

    Baseline assessments

    You will undergo baseline assessments to evaluate your current health status. These assessments include laboratory tests, electrocardiogram (ECG), and vital signs measurements such as blood pressure and pulse rate.

    Your tendon condition will be assessed using ultrasound-based shear wave elastography to measure tendon stiffness.

  3. Step 3

    Treatment administration

    You will receive a single injection of either NGI226 microparticles or a placebo. The injection is administered near the affected tendon.

    The injection is a powder mixed into a suspension for injection, and it is given through infiltration, which means it is injected directly into the area around the tendon.

  4. Step 4

    Follow-up visits

    You will have regular follow-up visits to monitor your response to the treatment. These visits will include checking for any side effects, changes in pain, swelling, or other symptoms.

    Additional assessments will be conducted to evaluate the safety and tolerability of the treatment, including laboratory tests and vital signs measurements.

  5. Step 5

    Final assessment

    At the end of the study period, a final assessment will be conducted to evaluate the overall effects of the treatment on your tendon condition.

    This will include a repeat of the ultrasound-based shear wave elastography to assess changes in tendon stiffness from the baseline.

Who can join the trial?

5 criteria

  • Must provide written informed consent before any study-specific procedures. This means you agree to participate after being informed about the study.
  • Must be an adult between 30 to 70 years old.
  • Must have Achilles tendinopathy, which is pain in the Achilles tendon, confirmed by a doctor through physical examination and imaging tests like ultrasound or MRI (Magnetic Resonance Imaging).
  • Symptoms must have been present for at least 8 weeks but less than 12 months.
  • Must have tried at least 6 weeks of conservative treatment without success. This includes methods like physiotherapy, taking NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), and using the RICE method (Rest, Ice, Compression, Elevation).

Who cannot join the trial?

9 criteria

  • Patients who have had surgery on their Achilles tendon in the past 6 months cannot participate.
  • Patients with a history of allergic reactions to similar treatments are not eligible.
  • Patients who are currently participating in another clinical trial are excluded.
  • Patients with severe medical conditions that could interfere with the study are not allowed to join.
  • Pregnant or breastfeeding women cannot take part in the study.
  • Patients who have received any other treatment for Achilles tendinopathy in the last 3 months are not eligible.
  • Patients with infections or skin conditions at the injection site are excluded.
  • Patients with a history of blood clotting disorders cannot participate.
  • Patients who are unable to follow the study procedures or attend follow-up visits are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

NGI226 microparticles are tiny particles designed to help heal and regenerate tendons, specifically in patients with Achilles tendinopathy. This condition affects the tendon at the back of your ankle, causing pain and difficulty in movement. The microparticles are injected around the tendon to see if they can improve healing and reduce symptoms. The study aims to find out if this treatment is safe and how well it works in helping the tendon recover.

What is already known about the treatment

NGI226 – NGI226 is administered as a single injection near the Achilles tendon, specifically targeting patients with Achilles tendinopathy. This medication is currently being studied in clinical trials to determine its safety and effectiveness in helping regenerate tendons. The main therapeutic use of NGI226 is to treat Achilles tendinopathy, a condition that causes pain and stiffness in the Achilles tendon. At the molecular level, NGI226 works by promoting the healing and regeneration of tendon tissue, although the exact mechanism is still under investigation. It is classified pharmacologically as a regenerative medicine, focusing on repairing damaged tissues.

Investigated diseases

Achilles Tendinopathy – Achilles tendinopathy is a condition that affects the Achilles tendon, which connects the calf muscles to the heel bone. It is characterized by pain, swelling, and stiffness in the tendon, particularly during physical activity. The condition often develops gradually, with symptoms worsening over time if not addressed. It is commonly seen in athletes and individuals who engage in activities that involve repetitive stress on the tendon. The progression of Achilles tendinopathy can lead to decreased flexibility and strength in the affected leg. In severe cases, it may result in difficulty walking or performing daily activities.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-500863-10-00Protocol codeCNGI226A12201Estimated enrolment46 patientsSponsorNovartis Pharma AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).